Vascular morphogenesis: Tales of two syndromes

Human Molecular Genetics

Volumn 12, Issue REV. ISS. 1, 2003, Pages

  Marchuk, Douglas A ^a   Srinivasan, Sudha ^a   Squire, Teresa L ^a   Zawistowski, Jon S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; INTEGRIN; MUTANT PROTEIN; REGULATOR PROTEIN;

ANGIOGENESIS; ANIMAL MODEL; ARTERIOVENOUS MALFORMATION; ARTERIOVENOUS SHUNT; AUTOSOMAL DOMINANT INHERITANCE; BLOOD VESSEL; CELL COMMUNICATION; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CEREBROVASCULAR MALFORMATION; CONGENITAL BLOOD VESSEL MALFORMATION; GENE CONTROL; GENE MUTATION; GENETIC ANALYSIS; GENETIC CODE; GENETIC DISORDER; GENETIC REGULATION; HUMAN; INHERITANCE; MORPHOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; REVIEW; VASODILATATION;

ACTIVIN RECEPTORS, TYPE I; ACTIVIN RECEPTORS, TYPE II; AMINO ACID MOTIFS; ANIMALS; ANTIGENS, CD; BLOOD VESSELS; BRAIN DISEASES; CELL ADHESION; CELL COMMUNICATION; CELL DIVISION; CYTOSKELETON; GENES, DOMINANT; HUMANS; INTEGRINS; MICE; MICE, KNOCKOUT; MICROTUBULE-ASSOCIATED PROTEINS; MODELS, BIOLOGICAL; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; SYNDROME; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE-1;

ANIMALIA;

EID: 0037390899     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (187)

1. Guttmacher, A.E., Marchuk, D.A. and White, R.I. Jr. (1995) Hereditary hemorrhagic telangiectasia. N. Engl. J. Med., 333, 918-924.
2. Braverman, I.M., Keh, A. and Jacobson, B.S. (1990) Ultrastructure and three-dimensional organization of the telangiectases of hereditary hemorrhagic telangiectasia. J. Invest. Dermatol., 95, 422-427.
3. McDonald, M.T., Papenberg, K.A., Ghosh, S., Glatfelter, A.A., Biesecker, B.B., Helmbold, E.A., Markel, D.S., Zolotor, A., McKinnon, W.C., Vanderstoep, J.L. et al. (1994) A disease locus for hereditary haemorrhagic telangiectasia maps to chromosome 9q33-34. Nat. Genet., 6, 197-204.
4. Shovlin, C.L., Hughes, J.M., Tuddenham, E.G., Temperley, I., Perembelon, Y.F., Scott, J., Seidman, C.E. and Seidman, J.G. (1994) A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q3. Nat. Genet., 6, 205-209.
5. Heutink, P., Haitjema, T., Breedveld, G.J., Janssen, B., Sandkuijl, L.A., Bontekoe, C.J., Westerman, C.J. and Oostra, B.A. (1994) Linkage of hereditary haemorrhagic telangiectasia to chromosome 9q34 and evidence for locus heterogeneity. J. Med. Genet., 31, 933-936.
6. McAllister, K.A., Grogg, K.M., Johnson, D.W., Gallione, C.J., Baldwin, M.A., Jackson, C.E., Helmbold, E.A., Markel, D.S., McKinnon, W.C., Murrell, J. et al. (1994) Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet., 8, 345-351.
7. Johnson, D.W., Berg, J.N., Gallione, C.J., McAllister, K.A., Warner, J.P., Helmbold, E.A., Markel, D.S., Jackson, C.E., Porteous, M.E. and Marchuk, D.A. (1995) A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genome Res., 5, 21-28.
8. Vincent, P., Plauchu, H., Hazan, J., Faure, S., Weissenbach, J. and Godet, J. (1995) A third locus for hereditary haemorrhagic telangiectasia maps to chromosome 12q [published erratum appears in Hum. Mol. Genet. 1995 4: 1243]. Hum. Mol. Genet., 4, 945-949.
9. Johnson, D.W., Berg, J.N., Baldwin, M.A., Gallione, C.J., Marondel, I., Yoon, S.J., Stenzel, T.T., Speer, M., Pericak-Vance, M.A., Diamond, A. et al. (1996) Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat. Genet., 13, 189-195.
10. Gougos, A. and Letarte, M. (1990) Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J. Biol. Chem., 265, 8361-8364.
11. Attisano, L., Carcamo, J., Ventura, F., Weis, F.M., Massague, J. and Wrana, J.L. (1993) Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell, 75, 671-680.
12. McAllister, K.A., Lennon, F., Bowles-Biesecker, B., McKinnon, W.C., Helmbold, E.A., Markel, D.S., Jackson, C.E., Guttmacher, A.E., Pericak-Vance, M.A. and Marchuk, D.A. (1994) Genetic heterogeneity in hereditary haemorrhagic telangiectasia: possible correlation with clinical phenotype. J. Med. Genet., 31, 927-932.
13. McAllister, K.A., Baldwin, M.A., Thukkani, A.K., Gallione, C.J., Berg, J.N., Porteous, M.E., Guttmacher, A.E. and Marchuk, D.A. (1995) Six novel mutations in the endoglin gene in hereditary hemorrhagic telangiectasia type 1 suggest a dominant-negative effect of receptor function. Hum. Mol. Genet., 4, 1983-1985.
14. Berg, J.N., Gallione, C.J., Stenzel, T.T., Johnson, D.W., Allen, W.P., Schwartz, C.E., Jackson, C.E., Porteous, M.E. and Marchuk, D.A. (1997) The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. Am. J. Hum. Genet., 61, 60-67.
15. Yamaguchi, H., Azuma, H., Shigekiyo, T., Inoue, H. and Saito, S. (1997) A novel missense mutation in the endoglin gene in hereditary hemorrhagic telangiectasia. Thromb. Haemost., 77, 243-247.
16. Shovlin, C.L., Hughes, J.M., Scott, J., Seidman, C.E. and Seidman, J.G. (1997) Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am. J. Hum. Genet., 61, 68-79.
17. Pece, N., Vera, S., Cymerman, U, White, R.I. Jr., Wrana, J.L. and Letarte, M. (1997) Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant negative. J. Clin. Invest., 100, 2568-2579.
18. Klaus, D.J., Gallione, C.J., Anthony, K., Yeh, E.Y., Yu, J., Lux, A., Johnson, D.W. and Marchuk, D.A. (1998) Novel missense and frameshift mutations in the activin receptor-like kinase-1 gene in hereditary hemorrhagic telangiectasia. Mutations in brief no. 164. Online. Hum. Mutat., 12, 137.
19. Gallione, C.J., Klaus, D.J., Yeh, E.Y., Stenzel, T.T., Xue, Y., Anthony, K.B., McAllister, K.A., Baldwin, M.A., Berg, J.N., Lux, A. et al. (1998) Mutation and expression analysis of the endoglin gene in hereditary hemorrhagic telangiectasia reveals null alleles. Hum. Mutat., 11, 286-294.
20. Abdalla, S.A., Pece-Barbara, N., Vera, S., Tapia, E., Paez, E., Bernabeu, C. and Letarte, M. (2000) Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2. Hum. Mol. Genet., 9, 1227-1237.
21. McDonald J.E., Miller, F.J., Hallam, S.E., Nelson, L., Marchuk, D.A. and Ward, K.J. (2000) Clinical manifestations in a large hereditary hemorrhagic telangiectasia (HHT) type 2 kindred. Am. J. Med. Genet., 93, 320-327.
22. Gallione, C.J., Scheessele, E.A., Reinhardt, D., Duits, A.J., Berg, J.N., Westermann, C.J. and Marchuk, D.A. (2000) Two common endoglin mutations in families with hereditary hemorrhagic telangiectasia in the Netherlands Antilles: evidence for a founder effect. Hum. Genet., 107, 40-44.
23. Cymerman, U., Vera, S., Pece-Barbara, N., Bourdeau, A., White, R.I. Jr., Dunn, J. and Letarte, M. (2000) Identification of hereditary hemorrhagic telangiectasia type 1 in newborns by protein expression and mutation analysis of endoglin. Pediatr Res., 47, 24-35.
24. Lin, W.D., Wu, J.Y., Hsu, H.B., Tsai, F.J., Lee, C.C. and Tsai, C.H. (2001) Mutation analysis of a family with hereditary hemorrhagic telangiectasia associated with hepatic arteriovenous malformation. J. Formos. Med. Assoc., 100, 817-819.
25. Kjeldsen, A.D., Brusgaard, K., Poulsen, L., Kruse, T., Rasmussen, K., Green, A. and Vase, P. (2001) Mutations in the ALK-1 gene and the phenotype of hereditary hemorrhagic telangiectasia in two large Danish families. Am. J. Med. Genet., 98, 298-302.
26. Trembath, R.C., Thomson, J.R., Machado, R.D., Morgan, N.V., Atkinson, C., Winship, I., Simonneau, G., Galie, N., Loyd, J.E., Humbert, M. et al. (2001) Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N. Engl. J. Med., 345, 325-334.
27. Olivieri, C., Mira, E., Delu, G., Pagella, F., Zambelli, A., Malvezzi, L., Buscarini, E. and Danesino, C. (2002) Identification of 13 new mutations in the ACVRL1 gene in a group of 52 unselected Italian patients affected by hereditary haemorrhagic telangiectasia. J. Med. Genet., 39, E39.
28. Pece-Barbara, N., Cymerman, U., Vera, S., Marchuk, D.A. and Letarte, M. (1999) Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1. Hum. Mol. Genet., 8, 2171-2181.
29. Lux, A., Attisano, L. and Marchuk, D.A. (1999) Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1. J. Biol. Chem., 274, 9984-9992.
30. Lux, A., Gallione, C.J. and Marchuk, D.A. (2000) Expression analysis of endoglin missense and truncation mutations: Insights into protein structure and disease mechanisms. Hum. Mol. Genet., 9, 745-755.
31. Paquet, M.E., Pece-Barbara, N., Vera, S., Cymerman, U., Karabegovic, A., Shovlin, C. and Letarte, M. (2001) Analysis of several endoglin mutants reveals no endogenous mature or secreted protein capable of interfering with normal endoglin function. Hum. Mol. Genet., 10, 1347-1357.
32. Piantanida, M., Buscarini, E., Dellavecchia, C., Minelli, A., Rossi, A., Buscarini, L. and Danesino, C. (1996) Hereditary haemorrhagic telangiectasia with extensive liver involvement is not caused by either HHT1 or HHT2. J. Med. Genet., 33, 441-443.
33. Wallace, G.M. and Shovlin, C.L. (2000) A hereditary haemorrhagic telangiectasia family with pulmonary involvement is unlinked to the known HHT genes, endoglin and ALK-1. Thorax, 55, 685-690.
34. Massague, J. (1998) TGF-beta signal transduction. Annu. Rev. Biochem., 67, 753-791.
35. Lin, H.Y., Wang, X.F., Ng-Eaton, E., Weinberg, R.A. and Lodish, H.F. (1992) Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell, 68, 775-785.
36. Wrana, J.L., Attisano, L., Carcamo, J., Zentella, A., Doody, J., Laiho, M., Wang, X.F. and Massague, J. (1992) TGF beta signals through a heteromeric protein kinase receptor complex. Cell, 71, 1003-1014.
37. Wrana, J.L., Attisano, L., Wieser, R., Ventura, F. and Massague, J. (1994) Mechanism of activation of the TGF-beta receptor. Nature, 370, 341-347.
38. Wieser, R., Wrana, J.L. and Massague, J. (1995) GS domain mutations that constitutively activate T beta R-1, the downstream signaling component in the TGF-beta receptor complex. EMBO J., 14, 2199-2208.
39. Ebner, R., Chen, R.H., Shum, L., Lawler, S., Zioncheck, T.F., Lee, A., Lopez, A.R. and Derynck, R. (1993) Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor. Science, 260, 1344-4348.
40. Lopez-Casillas, F., Wrana, J.L. and Massague, J. (1993) Betaglycan presents ligand to the TGF beta signaling receptor. Cell, 73, 1435-1444.
41. Lastres, P., Letamendia, A., Zhang, H., Rius, C., Almendro, N., Raab, U., Lopez, L.A., Langa, C., Fabra, A., Letarte, M. et al. (1996) Endoglin modulates cellular responses to TGF-beta 1. J. Cell. Biol., 133, 1109-1121.
42. Letamendia, A., Lastres, P., Botella, L.M., Raab, U., Langa, C., Velasco, B., Attisano, L. and Bernabeu, C. (1998) Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. J. Biol. Chem., 273, 33011-33019.
43. Piek, E., Westermark, U., Kastemar, M., Heldin, C.H., van Zoelen, E.J., Nister, M. and Ten Dijke, P. (1999) Expression of transforming-growth-factor (TGF)-beta receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF-beta1. Int. J. Cancer, 80, 756-763.
44. Heldin, C.H., Miyazono, K. and ten Dijke, P. (1997) TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature, 390, 465-471.
45. Attisano, L. and Wrana, J.L. (1998) Mads and Smads in TGF beta signalling. Curr. Opin. Cell. Biol., 10, 188-194.
46. Kretzschmar, M. and Massague, J. (1998) SMADs: mediators and regulators of TGF-beta signaling. Curr. Opin. Genet. Dev., 8, 103-111.
47. Macias-Silva, M., Abdollah, S., Hoodless, P.A., Pirone, R., Attisano, L. and Wrana, J.L. (1996) MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell, 87, 1215-1224.
48. Nakao, A., Imamura, T., Souchelnytskyi, S., Kawabata, M., Ishisaki, A., Oeda, E., Tamaki, K., Hanai, J., Heldin, C.H., Miyazono, K. et al. (1997) TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J., 16, 5353-5362.
49. Zhang, Y., Feng, X., We, R. and Derynck, R. (1996) Receptor-associated Mad homologues synergize as effectors of the TGF-beta response. Nature, 383, 168-172.
50. Liu, F., Pouponnot, C. and Massague, J. (1997) Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev., 11, 3157-3167.
51. Chen, Y.G. and Massague, J. (1999) Smad1 recognition and activation by the ALK1 group of transforming growth factor-beta family receptors. J. Biol. Chem., 274, 3672-3677.
52. Oh, S.P., Seki, T., Goss, K.A., Imamura, T., Yi, Y., Donahoe, P.K., Li, L., Miyazono, K., ten Dijke, P., Kim, S. et al. (2000) Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc. Natl Acad. Sci. USA, 97, 2626-2631.
53. Ota, T., Fujii, M., Sugizaki, T., Ishii, M., Miyazawa, K., Aburatani, H. and Miyazono, K. (2002) Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells. J. Cell Physiol., 193, 299-318.
54. Kretzschmar, M., Liu, E, Hata, A., Doody, J. and Massague, J. (1997) The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes Dev., 11, 984-995.
55. Gougos, A. and Letarte, M. (1988) Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J. Immunol., 141, 1925-1933.
56. ten Dijke, P., Yamashita, H., Ichijo, H., Franzen, P., Laiho, M., Miyazono, K. and Heldin, C.H. (1994) Characterization of type 1 receptors for transforming growth factor-b and activin. Science, 264, 101-104.
57. Goumans, M.J., Valdimarsdottir, G., Itoh, S., Rosendahl, A., Sideras, P. and ten Dijke, P. (2002) Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J., 21, 1743-1753.
58. Cheifetz, S., Bellon, T., Cales, C., Vera, S., Bernabeu, C., Massague, J. and Letarte, M. (1992) Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J. Biol. Chem., 267, 19027-19030.
59. Barbara, N.P., Wrana, J.L. and Letarte, M. (1999) Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J. Biol. Chem., 274, 584-594.
60. Pepper, M.S. (1997) Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev., 8, 21-43.
61. Conway, E.M., Collen, D. and Carmeliet, P. (2001) Molecular mechanisms of blood vessel growth. Cardiovasc. Res., 49, 507-521.
62. Lamouille, S., Mallet, C., Feige, J.J. and Bailly, S. (2002) Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood, 100, 4495-4501.
63. Li, D.Y., Sorensen, L.K., Brooke, B.S., Urness, L.D., Davis, E.C., Taylor, D.G., Boak, B.B. and Wendel, D.P. (1999) Defective angiogenesis in mice lacking endoglin. Science, 284, 1534-1537.
64. Bourdeau, A., Dumont, D.J. and Letarte, M. (1999) A murine model of hereditary hemorrhagic telangiectasia. J. Clin. Invest., 104, 1343-1351.
65. Arthur, H.M., Ure, J., Smith, A.J., Renforth, G., Wilson, D.I., Torsney, E., Charlton, R., Parums, D.V, Jowett, T., Marchuk, D.A. et al. (2000) Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev. Biol., 217, 42-53.
66. Jonker, L. and Arthur, H.M. (2002) Endoglin expression in early development is associated with vasculogenesis and angiogenesis. Mech. Dev, 110, 193-196.
67. Roelen, B.A., van Rooijen, M.A. and Mummery, C.L. (1997) Expression of ALK-1, a type 1 serine/threonine kinase receptor, coincides with sites of vasculogenesis and angiogenesis in early mouse development. Dev. Dyn., 209, 418-430.
68. Bourdeau, A., Faughnan, M.E. and Letarte, M. (2000) Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia. Trends Cardiovasc. Med., 10, 279-285.
69. Bourdeau, A., Faughnan, M.E., McDonald, M.L., Paterson, A.D., Wanless, I.R. and Letarte, M. (2001) Potential role of modifier genes influencing transforming growth factor-beta1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am. J. Pathol., 158, 2011-2020.
70. Urness, L.D., Sorensen, L.K. and Li, D.Y. (2000) Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat. Genet., 26, 328-331.
71. Srinivasan, S., Hanes, M.A., Dickens, T., Porteous, M.E.M., Oh, P.S., Hale, L.P. and Marchuk, D.A. (2003) A mouse model for HHT type 2. Hum. Mol. Genet., 12, 473-482.
72. Bauer, T., Britton, R, Lomas, D., Wight, D.G., Friend, P.J. and Alexander, G.J. (1995) Liver transplantation for hepatic arteriovenous malformation in hereditary haemorrhagic telangiectasia. J. Hepatol., 22, 586-590.
73. Martini, G.A. (1978) The liver in hereditary haemorrhagic teleangiectasia: an inborn error of vascular structure with multiple manifestations: a reappraisal. Gut, 19, 531-537.
74. Fagel, W.J., Perlberger, R. and Kaufmann, R.H. (1988) Portosystemic encephalopathy in hereditary hemorrhagic telangiectasia. Am. J. Med., 85, 858-860.
75. Bernard, G., Mion, F., Henry, L., Plauchu, H. and Paliard, P. (1993) Hepatic involvement in hereditary hemorrhagic telangiectasia: clinical, radiological, and hemodynamic studies of 11 cases. Gastroenterology, 105, 482-487.
76. Brohee, D., Franken, P., Fievez, M., Baudoux, M., Henuzet, C., Brasseur, P. and Struyven, J. (1984) High-output right ventricular failure secondary to hepatic arteriovenous microfistulae. Selective arterial embolization treatment. Arch. Intern. Med., 144, 1282-1284.
77. Boillot, O., Bianco, F., Viale, J.P., Mion, F., Mechet, I., Gille, D., Delaye, J., Paliard, P. and Plauchu, H. (1999) Liver transplantation resolves the hyperdynamic circulation in hereditary hemorrhagic telangiectasia with hepatic involvement. Gastroenterology, 116, 187-192.
78. Montejo Baranda, M., Perez, M., De Andres, J., De la Hoz, C., Merino, J. and Aguirre, C. (1984) High out-put congestive heart failure as first manifestation of Osler-Weber-Rendu disease. Angiology, 35, 568-576.
79. Sawabe, M., Arai, T., Esaki, Y., Tsuru, M., Fukazawa, T. and Takubo, K. (2001) Three-dimensional organization of the hepatic microvasculature in hereditary hemorrhagic telangiectasia. Arch. Pathol. Lab. Med., 125, 1219-1223.
80. Roman, B.L., Pham, V.N., Lawson, N.D., Kulik, M., Childs, S., Lekven, A.C., Garrity, D.M., Moon, R.T., Fishman, M.C., Lechleider, R.J. et al. (2002) Disruption of acvr11 increases endothelial cell number in zebrafish cranial vessels. Development, 129, 3009-3019.
81. Sanchez-Elsner, T., Botella, L.M., Velasco, B., Langa, C. and Bernabeu, C. (2002) Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J. Biol. Chem., 277, 43799-43808.
82. Sanchez-Elsner, T., Botella, L.M., Velasco, B., Corbi, A., Attisano, L. and Bernabeu, C. (2001) Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J. Biol. Chem., 276, 38527-38535.
83. Dagdeviren, A., Muftuoglu, S.F., Cakar, A.N. and Ors, U. (1998) Endoglin (CD 105) expression in human lymphoid organs and placenta. Anat. Anz., 180, 461-469.
84. Adam, P.J., Clesham, G.J. and Weissberg, P.L. (1998) Expression of endoglin mRNA and protein in human vascular smooth muscle cells. Biochem. Biophys. Res. Commun., 247, 33-37.
85. St-Jacques, S., Cymerman, U., Pece, N. and Letarte, M. (1994) Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells. Endocrinology, 134, 2645 2657.
86. Gougos, A., St Jacques, S., Greaves, A., O'Connell, P.J., d'Apice, A.J., Buhring, H.J., Bernabeu, C., van Mourik, J.A. and Letarte, M. (1992) Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int. Immunol., 4, 83-92.
87. Lastres, P, Bellon, T., Cabanas, C., Sanchez-Madrid, F., Acevedo, A., Gougos, A., Letarte, M. and Bernabeu, C. (1992) Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur. J. Immunol., 22, 393-397.
88. Buhring, H.J., Muller, C.A., Letarte, M., Gougos, A., Saalmuller, A., van Agthoven, A.J. and Busch, F.W. (1991) Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. Leukemia, 5, 841-847.
89. St-Jacques, S., Forte, M., Lye, S.J. and Letarte, M. (1994) Localization of endoglin, a transforming growth factor-beta binding protein, and of CD44 and integrins in placenta during the first trimester of pregnancy. Biol. Reprod., 51, 405-413.
90. Caniggia, I., Taylor, C.V, Ritchie, J.W, Lye, S.J. and Letarte, M. (1997) Endoglin regulates trophoblast differentiation along the invasive pathway in human placental villous explants. Endocrinology, 138, 4977-4988.
91. Zhang, E.G., Smith, S.K. and Charnock-Jones, D.S. (2002) Expression of CD105 (endoglin) in arteriolar endothelial cells of human endometrium throughout the menstrual cycle. Reproduction, 124, 703-711.
92. Ingman, W.V. and Robertson, S.A. (2002) Defining the actions of transforming growth factor beta in reproduction. Bioessays, 24, 904-914.
93. Chakraborty, C., Gleeson, L.M., McKinnon, T. and Lala, P.K. (2002) Regulation of human trophoblast migration and invasiveness. Can. J. Physiol. Pharmacol., 80, 116-124.
94. Cho, S.K., Bourdeau, A., Letarte, M. and Zuniga-Pflucker, J.C. (2001) Expression and function of CD105 during the onset of hematopoiesis from Flk1(+) precursors. Blood, 98, 3635-3642.
95. Chen, C.Z., Li, M., de Graaf, D., Monti, S., Gottgens, B., Sanchez, M.J., Lander, E.S., Golub, T.R., Green, A.R. and Lodish, H.F. (2002) Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells. Proc. Natl Acad. Sci. USA, 99, 15468-15473.
96. Akashi, K., He, X., Chen, J., Iwasaki, H., Niu, C., Steenhard, B., Zhang, J., Haug, J. and Li, L. (2003) Transcriptional accessibility for genes of multiple tissues and hematopoietic lineages is hierarchically controlled during early hematopoiesis. Blood, 101, 383-389.
97. Folkman, J. (2002) Role of angiogenesis in tumor growth and metastasis. Semin. Oncol., 29, 15-18.
98. Burrows, F.J., Derbyshire, E.J., Tazzari, P.L., Amlot, P., Gazdar, A.F., King, S.W., Letarte, M., Vitetta, E.S. and Thorpe, P.E. (1995) Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin. Cancer Res., 1, 1623-1634.
99. Bodey, B., Bodey, B. Jr., Siegel, S.E. and Kaiser, H.E. (1998) Upregulation of endoglin (CD 105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy. Anticancer Res., 18, 1485-1500.
100. Miller, D.W., Graulich, W., Karges, B., Stahl, S., Ernst, M., Ramaswamy, A., Sedlacek, H.H., Muller, R. and Adamkiewicz, J. (1999) Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int. J. Cancer, 81, 568-572.
101. Matsuno, F., Haruta, Y., Kondo, M., Tsai, H., Barcos, M. and Seon, B.K. (1999) Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin. Cancer Res., 5, 371-382.
102. Fonsatti, E., Del Vecchio, L., Altomonte, M., Sigalotti, L., Nicotra, M.R., Coral, S., Natali, P.G. and Maio, M. (2001) Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J. Cell. Physiol., 188, 1-7.
103. Takahashi, N., Haba, A., Matsuno, F. and Seon, B.K. (2001) Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res., 61, 7846-7854.
104. Lane, K.B., Machado, R.D., Pauciulo, M.W., Thomson, J.R., Phillips, J.A., 3rd, Loyd, J.E., Nichols, W.C. and Trembath, R.C. (2000) Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat. Genet., 26, 81-84.
105. Deng, Z., Morse, J.H., Slager, S.L., Cuervo, N., Moore, K.J., Venetos, G., Kalachikov, S., Cayanis, E., Fischer, S.G., Barst, R.J. et al. (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am. J. Hum. Genet., 67, 737-744.
106. Thomson, J.R., Machado, R.D., Pauciulo, M.W., Morgan, N.V., Humbert, M., Elliott, G.C., Ward, K., Yacoub, M., Mikhail, G., Rogers, P. et al. (2000) Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II a receptor member of the TGF-beta family. J. Med. Genet., 37, 741-745.
107. Alberts, M.J., Davis, J.R, Graffagnino, C., McClenny, C., Delong, D., Granger, C., Herbstreith, M.H., Boteva, K., Marchuk, D.A. and Roses, A.D. (1997) Endoglin gene polymorphism as a risk factor for sporadic intracerebral hemorrhage. Ann. Neurol., 41, 683-686.
108. Takenaka, K., Sakai, H., Yamakawa, H., Yoshimura, S., Kumagai, M., Nakashima, S., Nozawa, Y. and Sakai, N. (1999) Polymorphism of the endoglin gene in patients with intracranial saccular aneurysms. J. Neurosurg., 90, 935-938.
109. Krex, D., Ziegler, A., Schackert, H.K. and Schackert, G. (2001) Lack of association between endoglin intron 7 insertion polymorphism and intracranial aneurysms in a white population: evidence of racial/ethnic differences. Stroke, 32, 2689-2694.
110. Gil-Nagel, A., Wilcox, K.J., Stewart, J.M., Anderson, V.E., Leppik, I.E. and Rich, S.S. (1995) Familial cerebral cavernous angioma: clinical analysis of a family and phenotypic classification. Epilepsy Res., 21, 27-36.
111. Zabramski, J.M., Henn, J.S. and Coons, S. (1999) Pathology of cerebral vascular malformations. Neurosurg. Clin. N. Am., 10, 395-410.
112. Eerola, I., Plate, K.H., Spiegel, R., Boon, L.M., Mulliken, J.B. and Vikkula, M. (2000) KRIT1 is mutated in hyperkeratotic cutaneous capillary-venous malformation associated with cerebral capillary malformation. Hum. Mol. Genet., 9, 1351-1355.
113. Couteulx, S.L., Brezin, A.P., Fontaine, B., Tournier-Lasserve, E. and Labauge, P. (2002) A novel KRIT1/CCM1 truncating mutation in a patient with cerebral and retinal cavernous angiomas. Arch. Ophthalmol., 120, 217-218.
114. Davenport, W.J., Siegel, A.M., Dichgans, J., Drigo, P., Mammi, I., Pereda, P., Wood, N.W. and Rouleau, G.A. (2001) CCM1 gene mutations in families segregating cerebral cavernous malformations. Neurology, 56, 540-543.
115. Clatterbuck, R.E., Cohen, B., Gailloud, R, Murphy, K. and Rigamonti, D. (2002) Vertebral hemangiomas associated with familial cerebral cavernous malformation: segmental disease expression. Case report. J. Neurosurg., 97, 227-230.
116. Zabramski, J.M., Wascher, T.M., Spetzler, R.F., Johnson, B., Golfinos, J., Drayer, B.P., Brown, B., Rigamonti, D. and Brown, G. (1994) The natural history of familial cavernous malformations: results of an ongoing study. J. Neurosurg., 80, 422-432.
117. Kondziolka, D., Lunsford, L.D. and Kestle, J.R. (1995) The natural history of cerebral cavernous malformations. J. Neurosurg., 83, 820-824.
118. Dubovsky, J., Zabramski, J.M., Kurth, J., Spetzler, R.F., Rich, S.S., Orr, H.T. and Weber, J.L. (1995) A gene responsible for cavernous malformations of the brain maps to chromosome 7q. Hum. Mol. Genet., 4, 453-458.
119. Gunel, M., Awad, I.A., Anson, J. and Lifton, R.P. (1995) Mapping a gene causing cerebral cavernous malformation to 7q11.2-q21. Proc. Natl Acad. Sci. USA, 92, 6620-6624.
120. Marchuk, D.A., Gallione, C.J., Morrison, L.A., Clericuzio, C.L., Hart, B.L., Kosofsky, B.E., Louis, D.N., Gusella, J.F., Davis, L.E. and Prenger, V.L. (1995) A locus for cerebral cavernous malformations maps to chromosome 7q in two families. Genomics, 28, 311-314.
121. Craig, H.D., Gunel, M., Cepeda, O., Johnson, E.W, Ptacek, L., Steinberg, G.K., Ogilvy, C.S., Berg, M.J., Crawford, S.C., Scott, R.M. et al. (1998) Multilocus linkage identifies two new loci for a mendelian form of stroke, cerebral cavernous malformation, at 7p15-13 and 3q25.2-27. Hum. Mol. Genet., 7, 1851-1858.
122. Laberge-le Couteulx, X.S., Jung, H.H., Labauge, R, Houtteville, J.P., Lescoat, C., Celillon, M., Marechal, E., Joutel, A., Bach, J.F. and Tournier-Lasserve, E. (1999a) Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat. Genet., 23, 189-193.
123. Sahoo, T., Johnson, E.W., Thomas, J.W., Kuehl, P.M., Jones, T.L., Dokken, C.G., Touchman, J.W., Gallione, C.J., Lee-Lin, S.Q., Kosofsky, B. et al. (1999) Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations. Hum. Mol. Genet., 8, 2325-2333.
124. Zhang, J., Clatterbuck, R.E., Rigamonti, D. and Dietz, H.C. (2000) Mutations in KRIT1 in familial cerebral cavernous malformations. Neurosurgery, 46, 1272-1279.
125. Lucas, M., Solano, F., Zayas, M.D., Garcia-Moreno, J.M., Gamero, M.A., Costa, A.F. and Izquierdo, G. (2000) Spanish families with cerebral cavernous angioma do not bear 742C→T Hispanic American mutation of the KRIT1 gene. Ann. Neurol., 47, 836.
126. Sahoo, T., Goenaga-Diaz, E., Serebriiskii, I.G., Thomas, J.W., Kotova, E., Cuellar, J.G., Peloquin, J.M., Golemis, E., Bietinjanch, F., Green, E.D. et al. (2001) Computational and experimental analyses reveal previously undetected coding exons of the KRIT1 (CCM1) gene. Genomics, 71, 123-126.
127. Verlaan, D.J., Davenport, W.J., Stefan, H., Sure, U., Siegel, A.M. and Rouleau, G.A. (2002) Cerebral cavernous malformations: mutations in Krit1. Neurology, 58, 853-857.
128. Chen, D.H., Lipe, H.P., Qin, Z. and Bird, T.D. (2002) Cerebral cavernous malformation: novel mutation in a Chinese family and evidence for heterogeneity. J. Neurol. Sci., 196, 91-96.
129. Cave-Riant, F., Denier, C., Labauge, R, Cecillon, M., Maciazek, J., Joutel, A., Laberge-Le Couteulx, S. and Tournier-Lasserve, E. (2002) Spectrum and expression analysis of KRIT1 mutations in 121 consecutive and unrelated patients with Cerebral Cavernous Malformations. Eur. J. Hum. Genet., 10, 733-740.
130. Bretscher, A., Edwards, K. and Fehon, R.G. (2002) ERM proteins and merlin: integrators at the cell cortex. Nat. Rev. Mol. Cell. Biol., 3, 586-599.
131. Gary, R. and Bretscher, A. (1995) Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site. Mol. Biol. Cell., 6, 1061-1075.
132. Berryman, M., Gary, R. and Bretscher, A. (1995) Ezrin oligomers are major cytoskeletal components of placental microvilli: a proposal for their involvement in cortical morphogenesis. J. Cell. Biol., 131, 1231-1242.
133. Bretscher, A., Gary, R. and Berryman, M. (1995) Soluble ezrin purified from placenta exists as stable monomers and elongated dimers with masked C-terminal ezrin-radixin-moesin association domains. Biochemistry, 34, 16830-16837.
134. Matsui, T., Maeda, M., Doi, Y., Yonemura, S., Amano, M., Kaibuchi, K. and Tsukita, S. (1998) Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J. Cell. Biol., 140, 647-657.
135. Niggli, V., Andreoli, C., Roy, C. and Mangeat, P. (1995) Identification of a phosphatidylinositol-4,5-bisphosphate-binding domain in the N-terminal region of ezrin. FEBS Lett., 376, 172-176.
136. Hirao, M., Sato, N., Kondo, T., Yonemura, S., Monden, M., Sasaki, T., Takai, Y. and Tsukita, S. (1996) Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway. J. Cell. Biol., 135, 37-51.
137. Sedgwick, S.G. and Smerdon, S.J. (1999) The ankyrin repeat: a diversity of interactions on a common structural framework. Trends Biochem. Sci., 24, 311-316.
138. Serebriiskii, I., Estojak, J., Sonoda, G., Testa, J.R. and Golemis, E.A. (1997) Association of Krev-1/rap1a with Krit1, a novel ankyrin repeat-containing protein encoded by a gene mapping to 7q21-22. Oncogene, 15, 1043-1049.
139. Kitayama, H., Sugimoto, Y., Matsuzaki, T., Ikawa, Y. and Noda, M. (1989) A ras-related gene with transformation suppressor activity. Cell, 56, 77-84.
140. Bachrati, C.Z., Downes, C.S. and Rasko, I. (1999) Chemical reverse transformation of CHO-K1 cells induces changes in expression of a candidate tumour suppressor and of a gene not previously characterised as transformation related. Eur. J. Cell. Biol., 78, 561-566.
141. Bos, J.L. (1998) All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ra1. EMBO J., 17, 6776-6782.
142. Sebzda, E., Bracke, M., Tugal, T., Hogg, N. and Cantrell, D.A. (2002) Rap1A positively regulates T cells via integrin activation rather than inhibiting lymphocyte signaling. Nat. Immunol., 3, 251-258.
143. Wienecke, R., Konig, A. and DeClue, J.E. (1995) Identification of tuberin, the tuberous sclerosis-2 product. J. Biol. Chem., 270, 16407-16414.
144. Soucek, T., Pusch, O., Wienecke, R., DeClue, J.E. and Hengstschlager, M. (1997) Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase. J. Biol. Chem., 272, 29301-20308.
145. Zhang, J., Clatterbuck, R.E., Rigamonti, D., Chang, D.D. and Dietz, H.C. (2001) Interaction between krit1 and icap1 alpha infers perturbation of integrin beta1-mediated angiogenesis in the pathogenesis of cerebral cavernous malformation. Hum. Mol. Genet., 10, 2953-2960.
146. Zhang, J., Clatterbuck, R.E., Rigamonti, D. and Dietz, H.C.
147. Eerola, I., McIntyre, B. and Vikkula, M. (2001) Identification of eight novel 5′-exons in cerebral capillary malformation gene-1 (CCM1) encoding KRIT1. Biochim. Biophys. Acta, 1517, 464-467.
148. Verlaan, D.J., Siegel, A.M. and Rouleau, G.A. (2002) Krit1 missense mutations lead to splicing errors in cerebral cavernous malformation. Am. J. Hum. Genet., 70, 1564-1567.
149. Zawistowski, J.S., Serebriiskii, I.G., Lee, M.F., Golemis, E.A. and Marchuk, D.A. (2002) KRIT1 association with the integrin-binding protein ICAP-1: a new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis. Hum. Mol. Genet., 11, 389-396.
150. Chang, D.D., Wong, B.Q., Liu, J. and Springer, T.A. (2002) Molecular basis for interaction between Icap1 alpha PTB domain and beta 1 integrin. J. Biol. Chem., 277, 8140-8145.
151. Chang, D.D., Wong, C., Smith, H. and Liu, J. (1997) ICAP-1, a novel beta1 integrin cytoplasmic domain-associated protein, binds to a conserved and functionally important NPXY sequence motif of beta1 integrin. J. Cell. Biol., 138, 1149-1157.
152. Zhang, X.A. and Hemler, M.E. (1999) Interaction of the integrin beta1 cytoplasmic domain with ICAP-1 protein. J. Biol. Chem., 274, 11-19.
153. Degani, S., Balzac, F., Brancaccio, M., Guazzone, S., Retta, S.F., Silengo, L., Eva, A. and Tarone, G. (2002) The integrin cytoplasmic domain-associated protein ICAP-1 binds and regulates Rho family GTPases during cell spreading. J. Cell. Biol., 156, 377-387.
154. Bouvard. D. and Block, M.R. (1998) Calcium/calmodulin-dependent protein kinase II controls integrin alpha5beta1-mediated cell adhesion through the integrin cytoplasmic domain associated protein-1alpha. Biochem. Biophys. Res. Commun., 252, 46-50.
155. Fournier, H.N., Dupe-Manet, S., Bouvard, D., Lacombe, M.L., Marie, C., Block, M.R. and Albiges-Rizo, C. (2002) Integrin cytoplasmic domain-associated protein 1alpha (ICAP-1alpha ) interacts directly with the metastasis suppressor nm23-H2, and both proteins are targeted to newly formed cell adhesion sites upon integnin engagement. J. Biol. Chem.,277, 20895-20902.
156. Rupp, PA. and Little, C.D. (2001) Integrins in vascular development. Circ. Res., 89, 566-572.
157. Stephens, L.E., Sutherland, A.E., Klimanskaya, I.V, Andrieux, A., Meneses, J., Pedersen, R.A. and Damsky, C.H. (1995) Deletion of beta 1 integrins in mice results in inner cell mass failure and peri-implantation lethality. Genes Dev., 9, 1883-1895.
158. Fassler, R. and Meyer, M. (1995) Consequences of lack of beta 1 integrin gene expression in mice. Genes Dev, 9, 1896-1908.
159. Bauer, J., Margolis, M., Schreiner, C., Edgell, C.J., Azizkhan, J., Lazarowski, E. and Juliano, R.L. (1992) In vitro model of angiogenesis using a human endothelium-derived permanent cell line: contributions of induced gene expression, G-proteins, and integrins. J. Cell. Physiol., 153, 437-449.
160. Davis, G.E. and Camarillo, C.W. (1995) Regulation of endothelial cell morphogenesis by integrins, mechanical forces, and matrix guidance pathways. Exp. Cell. Res., 216, 113-123.
161. Bloch, W., Forsberg, E., Lentini, S., Brakebusch, C., Martin, K., Krell, H.W., Weidle, U.H., Addicks, K. and Fassler, R. (1997) Beta 1 integrin is essential for teratoma growth and angiogenesis. J. Cell. Biol., 139, 265-278.
162. Milner, R. and Campbell, I.L. (2002) Developmental regulation of beta1 integrins during angiogenesis in the central nervous system. Mol. Cell. Neurosci., 20, 616-626.
163. McCarty, J.H., Monahan-Earley, R.A., Brown, L.F., Keller, M., Gerhardt, H., Rubin, K., Shani, M., Dvorak, H.F., Wolburg, H., Bader, B.L. et al. (2002) Defective associations between blood vessels and brain parenchyma lead to cerebral hemorrhage in mice lacking alphav integrins. Mol. Cell. Biol., 22, 7667-7677.
164. Faisst, A.M. and Gruss, P. (1998) Bodenin: a novel murine gene expressed in restricted areas of the brain. Dev. Dyn., 212, 293-303.
165. Kehrer-Sawatzki, H., Wilda, M., Braun, V.M., Richter, H.P. and Hameister, H. (2002) Mutation and expression analysis of the KRIT1 gene associated with cerebral cavernous malformations (CCM1). Acta Neuropathol. (Berl.), 104, 231-240.
166. Denier, C., Gasc, J.M., Chapon, F., Domenga, V., Lescoat, C., Joutel, A. and Tournier-Lasserve, E. (2002) Krit1/cerebral cavernous malformation 1 mRNA is preferentially expressed in neurons and epithelial cells in embryo and adult. Mech. Dev., 117, 363-367.
167. Bronner-Fraser, M. (1987) Perturbation of cranial neural crest migration by the HNK-1 antibody. Dev. Biol., 123, 321-331.
168. Jones, L.S. and Grooms, S.Y. (1997) Normal and aberrant functions of integrins in the adult central nervous system. Neurochem. Int., 31, 587-595.
169. Akiyama, H., Kawamata, T., Dedhar, S. and McGeer, P.L. (1991) Immunohistochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer brain tissue. J. Neuroimmunol., 32, 19-28.
170. Staubli, U., Vanderklish, P. and Lynch, G. (1990) An inhibitor of integrin receptors blocks long-term potentiation. Behav. Neural. Biol., 53, 1-5.
171. Fogerty, F.J., Akiyama, S.K., Yamada, K.M. and Mosher, D.F. (1990) Inhibition of binding of fibronectin to matrix assembly sites by anti-integrin (alpha 5 beta 1) antibodies. J. Cell. Biol., 111, 699-708.
172. Brassard, D.L., Maxwell, E., Malkowski, M., Nagabhushan, T.L., Kumar, C.C. and Armstrong, L. (1999) Integrin alpha(v)beta(3)-mediated activation of apoptosis. Exp. Cell. Res., 251, 33-45.
173. Stupack, D.G., Puente, X.S., Boutsaboualoy, S., Storgard, C.M. and Cheresh, D.A. (2001) Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J. Cell. Biol., 155, 459-470.
174. Kozlova, N.I., Morozevich, G.E., Chubukina, A.N. and Berman, A.E. (2001) Integrin alphavbeta3 promotes anchorage-dependent apoptosis in human intestinal carcinoma cells. Oncogene, 20, 4710-4717.
175. Stupack, D.G. and Cheresh, D.A. (2002) ECM remodeling regulates angiogenesis: endothelial integrins look for new ligands. Sci STKE, 2002, PE7.
176. Clatterbuck, R.E., Eberhart, C.G., Crain, B.J. and Rigamonti, D. (2001) Ultrastructural and immunocytochemical evidence that an incompetent blood-brain barrier is related to the pathophysiology of cavernous malformations. J. Neurol. Neurosurg. Psychiatry, 71, 188-192.
177. Gunel, M., Laurans, M.S., Shin, D., DiLuna, M.L., Voorhees, J., Choate, K., Nelson-Williams, C. and Lifton, R.P. (2002) KRIT1, a gene mutated in cerebral cavernous malformation, encodes a microtubule-associated protein. Proc. Natl Acad. Sci. USA, 99, 10677-10682.
178. Schuyler, S.C. and Pellman, D. (2001) Microtubule 'plus-end-tracking proteins': the end is just the beginning. Cell, 105, 421-424.
179. Tsukamoto, N., Hattori, M., Yang, H., Bos, J.L. and Minato, N. (1999) Rap1 GTPase-activating protein SPA-1 negatively regulates cell adhesion. J. Biol. Chem., 274, 18463-18469.
180. Reedquist, K.A., Ross, E., Koop, E.A., Wolthuis, R.M., Zwartkruis, F.J., van Kooyk, Y., Salmon, M., Buckley, C.D. and Bos, J.L. (2000) The small GTPase, Rap1, mediates CD31-induced integrin adhesion. J. Cell. Biol., 148, 1151-1158.
181. Katagiri, K., Hattori, M., Minato, N., Irie, S., Takatsu, K. and Kinashi, T. (2000) Rap1 is a potent activation signal for leukocyte function-associated antigen 1 distinct from protein kinase C and phosphatidylinositol-3-OH kinase. Mol. Cell. Biol., 20, 1956-1969.
182. de Bruyn, K.M., Rangarajan, S., Reedquist, K.A., Figdor, C.G. and Bos, J.L. (2002) The small GTPase Rap1 is required for Mn(2+)- and antibody-induced LFA-1- and VLA-4-mediated cell adhesion. J. Biol. Chem.,277, 29468-29476.
183. Arai, A., Nosaka, Y., Kanda, E., Yamamoto, K., Miyasaka, N. and Miura, O. (2001) Rap1 is activated by erythropoietin or interleukin-3 and is involved in regulation of beta1 integrin-mediated hematopoietic cell adhesion. J. Biol. Chem., 276, 10453-10462.
184. Ruggieri, R., Bender, A., Matsui, Y., Powers, S., Takai, Y., Pringle, J.R. and Matsumoto, K. (1992) RSR1 a ras-like gene homologous to Krev-1 (smg21A/rap1A): role in the development of cell polarity and interactions with the Ras pathway in Saccharomyces cerevisiae. Mol. Cell. Biol., 12, 758-766.
185. Palazzo, A.F, Joseph, H.L., Chen, Y.J., Dujardin, D.L., Alberts, A.S., Pfister, K.K., Vallee, R.B. and Gundersen, G.G. (2001) Cdc42, dynein, and dynactin regulate MTOC reorientation independent of Rho-regulated microtubule stabilization. Curr. Biol., 11, 1536-1541.
186. Ueda, H., Morishita, R., Yamauchi, J., Itoh, H., Kato, K. and Asano, T. (2001) Regulation of Rac and Cdc42 pathways by G(i) during lysophosphatidic acid-induced cell spreading. J. Biol. Chem., 276, 6846-6852.
187. Lee, J.S. and Gotheb, A.I. (2002) Microtubule-actin interactions may regulate endothelial integrity and repair. Cardiovasc. Pathol., 11, 135-140.